Posted by Michael Wonder on 02 Aug 2023
Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies
1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies comparing them to established active ingredients.
Placebo comparisons are unsuitable for assessing an additional benefit.
